Gee‐Chen Chang

9.1k citations

55 papers · 3.3k indexed · 1 hit paper · h-index 31

Cancer Research top 2%
- Cancer Genomics and Diagnostics 5
Oncology top 2%
- Lung Cancer Research Studies 10
- Colorectal Cancer Treatments and Studies 9
- Peptidase Inhibition and Analysis 5
- Cancer-related Molecular Pathways 4
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations 30
- Lung Cancer Diagnosis and Treatment 13
Molecular Biology top 5%
- RNA modifications and cancer 4
Neurology top 10%

Co-authors: Pan‐Chyr Yang Chih‐Yi Chen Sung‐Liang Yu Jeremy J.W. Chen Hsuan‐Yu Chen James Chih‐Hsin Yang Chiou-Ling Cheng Wing‐Kai Chan
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Partner nations: Taiwan United States China

In The Last Decade

Gee‐Chen Chang

54 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Gee‐Chen Chang

Since Specialization

Citations

This map shows the geographic impact of Gee‐Chen Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gee‐Chen Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gee‐Chen Chang more than expected).

Fields of papers citing papers by Gee‐Chen Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gee‐Chen Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gee‐Chen Chang. The network helps show where Gee‐Chen Chang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gee‐Chen Chang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gee‐Chen Chang Line = papers co-authored together Gee‐Chen Chang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Tp53 determines the spatial dynamics of M1/M2 tumor-associated macrophages and M1-driven tumoricidal effects Yi‐Jing Hsiao,Min-Shu Hsieh,Gee‐Chen Chang,Yin-Chen Hsu,C Y Wang,Yan-Ming Chen,Yi-Ling Chen,Pan‐Chyr Yang,Sung‐Liang Yu	2025	4
2	Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation Ming-Liang Peng,Yen-Hsiang Huang,Kuo-Hsuan Hsu,Jeng‐Sen Tseng,Po-Hsin Lee,Kun‐Chieh Chen,Gee‐Chen Chang,Tsung-Ying Yang	2024	1
3	Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients Kuo-Hsuan Hsu,Jing-Wen Huang,Jeng‐Sen Tseng,Kuan‐Wen Chen,Yih-Chyang Weng,Sung‐Liang Yu,Tsung‐Ying Yang,Yen-Hsiang Huang,Jeremy J.W. Chen,Kun‐Chieh Chen,Gee‐Chen Chang	2021	11
4	Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women Tzu‐Yu Chen,Yao‐Hwei Fang,Huiling Chen,Chin‐Hao Chang,Hsin Huang,Yi-Song Chen,Kuo-Meng Liao,Hsiao-Yu Wu,Gee‐Chen Chang,Ying-Huang Tsai,Chih-Liang Wang,Yuh-Min Chen,Ming-Shyan Huang,Wu‐Chou Su,Pan‐Chyr Yang,Chien‐Jen Chen,Chin‐Fu Hsiao,Chao A. Hsiung	2020	58
5	A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients Giorgio V. Scagliotti,Denis Moro‐Sibilot,Jens Kollmeier,Adolfo Favaretto,Eun Kyung Cho,Heidrun Grosch,Martin Kimmich,Nicolas Girard,Chun-Ming Tsai,Te‐Chun Hsia,Matteo Brighenti,Christian Schumann,Xuejing Aimee Wang,Sameera R. Wijayawardana,Aaron M. Gruver,Johan Wallin,Kambiz Mansouri,Volker Wacheck,Gee‐Chen Chang	2019	60
6	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report James Chih‐Hsin Yang,Frances A. Shepherd,Dong‐Wan Kim,Gyeong‐Won Lee,Jong Seok Lee,Gee‐Chen Chang,Sung Sook Lee,Yu‐Feng Wei,Yun Gyoo Lee,Gianluca Laus,Barbara Collins,Francesca Pisetzky,Leora Horn	2019	164
7	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer Thomas John,Hiroaki Akamatsu,Angelo Delmonte,Wu‐Chou Su,Jong Seok Lee,Gee‐Chen Chang,Xiangning Huang,Suzanne Jenkins,Yi‐Long Wu	2018	35
8	FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression Chia-Ying Hsu,Gee‐Chen Chang,Yi‐Ju Chen,Yi‐Chiung Hsu,Yi‐Jing Hsiao,Kang‐Yi Su,Hsuan‐Yu Chen,Chien‐Yu Lin,Jin‐Shing Chen,Yu‐Ju Chen,Qi-Sheng Hong,Wen-Hui Ku,Chih‐Ying Wu,Bing‐Ching Ho,Ching-Cheng Chiang,Pan‐Chyr Yang,Sung‐Liang Yu	2017	26
9	A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma Tony Mok,Sarayut Lucien Geater,Wu‐Chou Su,Eng-Huat Tan,James Chih‐Hsin Yang,Gee‐Chen Chang,May Han,Philip Komarnitsky,Francis Payumo,Jennifer Garrus,Sandra Close,Keunchil Park	2016	41
10	HOXA5 Inhibits Metastasis via Regulating Cytoskeletal Remodelling and Associates with Prolonged Survival in Non-Small-Cell Lung Carcinoma Chi-Chung Wang,Kang‐Yi Su,Hsuan‐Yu Chen,So-Yi Chang,Chi-Fan Shen,Chia-Hung Hsieh,Qi-Sheng Hong,Ching-Cheng Chiang,Gee‐Chen Chang,Sung‐Liang Yu,Jeremy J.W. Chen	2015	40
11	Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma Jeng‐Sen Tseng,Chih-Liang Wang,Tsung‐Ying Yang,Chih‐Yi Chen,Cheng‐Ta Yang,Kun‐Chieh Chen,Kuo-Hsuan Hsu,C. J. Tsai,Gee‐Chen Chang	2015	13
12	Shisa3 is Associated with Prolonged Survival Through Promoting β-Catenin Degradation in Lung Cancer Chun-Chieh Chen,Hsuan‐Yu Chen,Kang‐Yi Su,Qi-Sheng Hong,Bo‐Shiun Yan,Ching‐Hsien Chen,Szu‐Hua Pan,Yih‐Leong Chang,Chia-Jen Wang,Pei-Fang Hung,Shinsheng Yuan,Gee‐Chen Chang,Jeremy J.W. Chen,Pan‐Chyr Yang,Ya‐Chien Yang,Sung‐Liang Yu	2014	33
13	The Motor Protein KIF14 Inhibits Tumor Growth and Cancer Metastasis in Lung Adenocarcinoma Pei-Fang Hung,Tse‐Ming Hong,Yi‐Chiung Hsu,Hsuan‐Yu Chen,Yih‐Leong Chang,Chen‐Tu Wu,Gee‐Chen Chang,Yuh‐Shan Jou,Szu‐Hua Pan,Pan‐Chyr Yang	2013	38
14	EGFR L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients Shi‐Yi Yang,Tsung‐Ying Yang,Kun‐Chieh Chen,Yao-Jen Li,Kuo-Hsuan Hsu,Chi-Rne Tsai,Chih‐Yi Chen,Chung-Ping Hsu,Jiun‐Yi Hsia,Cheng-Yen Chuang,Ying-Huang Tsai,Kuan‐Yu Chen,Ming-Shyan Huang,Wu‐Chou Su,Yuh-Min Chen,Chao A. Hsiung,Chen‐Yang Shen,Gee‐Chen Chang,Pan‐Chyr Yang,Chien‐Jen Chen	2011	26
15	A Four-Gene Signature from NCI-60 Cell Line for Survival Prediction in Non–Small Cell Lung Cancer Yi‐Chiung Hsu,Shinsheng Yuan,Hsuan‐Yu Chen,Sung‐Liang Yu,Chia-Hsin Liu,Pin-Yen Hsu,Guani Wu,Chia‐Hung Lin,Gee‐Chen Chang,Ker-Chau Li,Pan‐Chyr Yang	2009	42
16	Claudin-1 Is a Metastasis Suppressor and Correlates with Clinical Outcome in Lung Adenocarcinoma Yu-Chih Chao,Szu‐Hua Pan,Shuenn-Chen Yang,Sung‐Liang Yu,Ting-Fang Che,Chung‐Wu Lin,Mu-Shiun Tsai,Gee‐Chen Chang,Che-Hsiang Wu,Yi-Ying Wu,Yung‐Chie Lee,Tse‐Ming Hong,Pan‐Chyr Yang	2008	146
17	Identification of α-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes Gee‐Chen Chang,Ko‐Jiunn Liu,Chia‐Ling Hsieh,Tsai-Shu Hu,Suparat Charoenfuprasert,Hsiung-Kun Liu,Kwen‐Tay Luh,Li‐Han Hsu,Chew-Wen Wu,Chou‐Chik Ting,Chih‐Yi Chen,Kun‐Chieh Chen,Tsung‐Ying Yang,Teh‐Ying Chou,Wen-Hua Wang,Jacqueline Whang‐Peng,Neng-Yao Shih	2006	128
18	Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer James Chih‐Hsin Yang,Jin‐Yuan Shih,Kun‐Chieh Chen,Chong‐Jen Yu,Tsung‐Ying Yang,Ching‐Pei Lin,Wen‐Pin Su,Chien‐Hung Gow,Chiun Hsu,Gee‐Chen Chang,Pan‐Chyr Yang	2006	51
19	Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway Gee‐Chen Chang,Shih-Lan Hsu,Jia-Rong Tsai,Wenjun Wu,Chih‐Yi Chen,Gwo‐Tarng Sheu	2004	55
20	Increased expression of cytochrome P4501B1 in peripheral leukocytes from lung cancer patients Ming‐Fang Wu,Wenjun Wu,Gee‐Chen Chang,Chin‐Yi Chen,Suh-Woan Hu,Wen-Tin Tsai,Huei Lee,Pinpin Lin	2004	24

About Gee‐Chen Chang

Gee‐Chen Chang is a scholar working on Microbiology, Oncology and Pulmonary and Respiratory Medicine, having authored 55 papers that have together received 3.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (13 papers), Lung Cancer Research Studies (10 papers), Colorectal Cancer Treatments and Studies (9 papers), Peptidase Inhibition and Analysis (5 papers), Cancer Genomics and Diagnostics (5 papers), Cancer-related Molecular Pathways (4 papers) and RNA modifications and cancer (4 papers). The work is most often cited by research in Cancer Research (784 citations), Oncology (1.4k citations) and Pulmonary and Respiratory Medicine (1.6k citations). Gee‐Chen Chang has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Pan‐Chyr Yang, Chih‐Yi Chen, Sung‐Liang Yu, Jeremy J.W. Chen, Hsuan‐Yu Chen, James Chih‐Hsin Yang, Chiou-Ling Cheng, Wing‐Kai Chan, Wei J. Chen and Chun‐Houh Chen.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact